| Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer G Vandekerkhove, WJ Struss, M Annala, HML Kallio, D Khalaf, ... European urology 75 (4), 667-675, 2019 | 110 | 2019 |
| Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder CancerctDNA Alterations in Metastatic Bladder Cancer G Vandekerkhove, T Todenhöfer, M Annala, WJ Struss, A Wong, K Beja, ... Clinical Cancer Research 23 (21), 6487-6497, 2017 | 100 | 2017 |
| Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerctDNA-Based Assessment of MMRd Prostate Cancer E Ritch, SYF Fu, C Herberts, G Wang, EW Warner, E Schönlau, ... Clinical Cancer Research 26 (5), 1114-1125, 2020 | 43 | 2020 |
| Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer G Vandekerkhove, JM Lavoie, M Annala, AJ Murtha, N Sundahl, S Walz, ... Nature communications 12 (1), 1-12, 2021 | 38 | 2021 |
| Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer C Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, H Xue, D Lin, ... European urology 78 (6), 834-844, 2020 | 31 | 2020 |
| Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma ECP Chedgy, G Vandekerkhove, C Herberts, M Annala, AJ Donoghue, ... The Journal of pathology 246 (2), 244-253, 2018 | 28 | 2018 |
| BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical AggressionBRCA2, ATM, and CDK12 in Prostate Cancer E Warner, C Herberts, S Fu, S Yip, A Wong, G Wang, E Ritch, AJ Murtha, ... Clinical Cancer Research 27 (6), 1650-1662, 2021 | 23 | 2021 |
| Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA E Ritch, AW Wyatt Urologic Oncology: Seminars and Original Investigations 36 (8), 380-384, 2018 | 15 | 2018 |
| Enhancing knowledge discovery from cancer genomics data with Galaxy MA Albuquerque, BM Grande, EJ Ritch, P Pararajalingam, S Jessa, ... Giga Science 6 (5), gix015, 2017 | 5 | 2017 |
| Genome-wide CRISPR screen reveals SLFN11 as a potent mediator of cisplatin sensitivity in muscle-invasive bladder cancer G Kumar, E Ritch, HZ Oo, CK Wang, D Tortora, D Thaper, I Moskalev, ... Urologic Oncology: Seminars and Original Investigations 38 (12), 905, 2020 | 1 | 2020 |
| Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer C Herberts, M Annala, J Sipola, SWS Ng, XE Chen, A Nurminen, ... Nature, 1-10, 2022 | | 2022 |
| Clonal architecture and evolution of treatment-resistant prostate cancer via deep whole-genome ctDNA sequencing C Herberts, M Annala, J Sipola, SW Ng, XE Chen, A Nurminen, ... Cancer Research 82 (12_Supplement), 3625-3625, 2022 | | 2022 |
| Multi-focal genomic dissection of synchronous primary and metastatic tissue from de novo metastatic prostate cancer E Warner, K Van der Eecken, AJ Murtha, EM Kwan, SW Ng, XE Chen, ... Cancer Research 82 (12_Supplement), 41-41, 2022 | | 2022 |
| Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer NM Fonseca, K Van der Eecken, C Herberts, S Verbeke, SWS Ng, ... JCO Precision Oncology 6, e2100543, 2022 | | 2022 |
| Somatic Features of Response and Relapse in Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy JVW Bacon, DC Müller, E Ritch, M Annala, SG Dugas, C Herberts, ... European Urology Oncology, 2021 | | 2021 |
| Somatic features of response and relapse in non-muscle invasive bladder cancer treated with intravesical Bacillus Calmette-Guerin DC Muller, JVW Bacon, E Ritch, SG Dugas, G Vandekerkhove, M Annala, ... EUROPEAN UROLOGY 79, S617-S617, 2021 | | 2021 |
| Genomic features of lung-recurrent hormone sensitive prostate cancer K Van der Eecken, N Fonseca, C Herberts, S Verbeke, S Ng, N Lumen, ... Belgian Week of Pathology, 2021 | | 2021 |
| Regulation of PPARγ expression in luminal muscle invasive bladder cancer D Tortora, R Morgan, G Kumar, E Ritch, B McConeghy, S Sinha, ... Urologic Oncology: Seminars and Original Investigations 38 (12), 905, 2020 | | 2020 |
| Identifying the genomic and clinical features of AKT1/PIK3CA mutant metastatic prostate cancer using circulating tumor DNA CM Herberts, AJ Murtha, S Fu, G Wang, E Schonlau, A Gleave, S Yip, ... CLINICAL CANCER RESEARCH 26 (11), 46-47, 2020 | | 2020 |
| Abstract A24: Identifying the genomic and clinical features of AKT1/PIK3CA mutant metastatic prostate cancer using circulating tumor DNA CM Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, A Gleave, S Yip, ... Clinical Cancer Research 26 (11_Supplement), A24-A24, 2020 | | 2020 |
